ASCO 2026: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC - Pharmaceutical Technology

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi. This study also emphasises the importance of molecular biomarker testing in prostate cancer. The top line Phase III results announced by Pfizer showed that talazoparib with enzalutamide has a favourable overall survival (OS) trend compared to enzalutamide with placebo. Credit: YES Market Media / Shutterstock.com. At the 2026 American Society of Clinical Oncology (ASCO) annual congress, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, which is evaluating the poly(ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) combined with…

Source: Pharmaceutical Technology